影像学诊断肝细胞癌:系统综述与Meta分析
该系统综述与Meta分析比较了多期CT、细胞外对比剂增强MRI和钆塞酸增强MRI在肝硬化患者中诊断肝细胞癌的表现,并评估了不确定性结节的最佳处理方式。19项综合比较显示MRI较CT敏感度更高(0.82 vs 0.66)、阴性似然比更低(0.20 vs 0.37),特异度与阳性似然比无差异;无研究比较活检与重复影像或替代影像。
要点
- MRI较CT诊断肝硬化患者HCC的敏感度更高(0.82 vs 0.66),阴性似然比更低(0.20 vs 0.37)。
- MRI与CT的特异度(0.91 vs 0.92)和阳性似然比(8.8 vs 8.1)无差异。
- 三种影像方法对≥2 cm的HCC诊断表现均更好,对<1 cm的HCC诊断表现均较差。
核心结论
- CT、细胞外对比剂增强MRI或钆塞酸增强MRI在肝硬化患者HCC诊断中无法明确优选哪一种。
- 对于肝硬化伴不确定性肿块的患者,比较活检与重复横断面成像或替代成像的数据不足。
研究设计与样本
- 系统综述与Meta分析,检索多个数据库自建库至2016年4月27日,纳入比较CT与细胞外对比剂增强MRI或钆塞酸增强MRI诊断成人肝硬化疑似HCC的研究。
- 共纳入33项研究,其中19项为综合比较,14项仅报告敏感度。
主要发现
- 19项综合比较显示,MRI较CT敏感度显著更高(0.82 vs 0.66),阴性似然比更低(0.20 vs 0.37)。
- MRI与CT的特异度(0.91 vs 0.92)和阳性似然比(8.8 vs 8.1)无差异。
- 三种影像方法对≥2 cm的HCC诊断表现均更好,对<1 cm的HCC诊断表现均较差。
- 无研究评估肝硬化伴不确定性结节患者采用活检、重复成像或替代成像哪种评估方式最佳。
关键数值与推荐
- MRI较CT诊断肝硬化患者HCC的敏感度为0.82 vs 0.66,阴性似然比为0.20 vs 0.37。
- MRI与CT的特异度为0.91 vs 0.92,阳性似然比为8.8 vs 8.1,均无差异。
- 对≥2 cm的HCC,三种影像方法诊断表现均更好;对<1 cm的HCC,诊断表现均较差。
临床怎么用
- 原文未据此给出推荐。
- 作者结论指出CT、细胞外对比剂增强MRI或钆塞酸增强MRI在肝硬化患者HCC诊断中无法明确优选哪一种。
- 作者结论指出肝硬化伴不确定性肿块患者中比较活检与重复横断面成像或替代成像的数据不足。
局限性
- 对发表偏倚的担忧、研究结果不一致、偏倚风险增加以及临床因素限制了支持单独使用钆塞酸增强MRI或细胞外对比剂增强MRI优于CT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Multiphasic computed tomography (CT) and magnetic resonance imaging (MRI) are both used for noninvasive diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis. To determine if there is a relative diagnostic benefit of one over the other, we synthesized evidence regarding the relative performance of CT, extracellular contrast-enhanced MRI, and gadoxetate-enhanced MRI for diagnosis of HCC in patients with cirrhosis. We also assessed whether liver biopsy versus follow-up with the same versus alternative imaging is best for CT-indeterminate or MRI-indeterminate liver nodules in patients with cirrhosis. We searched multiple databases from inception to April 27, 2016, for studies comparing CT with extracellular contrast-enhanced MRI or gadoxetate-enhanced MRI in adults with cirrhosis and suspected HCC. Two reviewers independently selected studies and extracted data. Of 33 included studies, 19 were comprehensive, while 14 reported sensitivity only. For all tumor sizes, the 19 comprehensive comparisons showed significantly higher sensitivity (0.82 versus 0.66) and lower negative likelihood ratio (0.20 versus 0.37) for MRI over CT. The specificities of MRI versus CT (0.91 versus 0.92) and the positive likelihood ratios (8.8 versus 8.1) were not different. All three modalities performed better for HCCs ≥2 cm. Performance was poor for HCCs <1 cm. No studies examined whether adults with cirrhosis and an indeterminate nodule are best evaluated using biopsy, repeated imaging, or alternative imaging. Concerns about publication bias, inconsistent study results, increased risk of bias, and clinical factors precluded support for exclusive use of either gadoxetate-enhanced or extracellular contrast-enhanced MRI over CT. CONCLUSION: CT, extracellular contrast-enhanced MRI, or gadoxetate-enhanced MRI could not be definitively preferred for HCC diagnosis in patients with cirrhosis; in patients with cirrhosis and an indeterminate mass, there were insufficient data comparing biopsy to repeat cross-sectional imaging or alternative imaging. (Hepatology 2018;67:401-421).
引用
- Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. Hepatology. 2017. PMID: 28859233. doi:10.1002/hep.29487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。